Coated-platelet levels are influenced by smoking, aspirin, and selective serotonin reuptake inhibitors [2]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 10, 2007, Pages 2149-2151

  Prodan, Calin I ^a,b,d   Joseph, P M ^b   Vincent, A S ^c   Dale, G L ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD SAMPLING; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; LETTER; MALE; NEGRO; NORMAL HUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; THROMBOCYTE ACTIVATION; THROMBOCYTOPOIESIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; ETHNIC GROUPS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLATELET COUNT; SEROTONIN UPTAKE INHIBITORS; SMOKING;

EID: 34548853423     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02691.x     Document Type: Letter

References (13)

1. Dale GL. Coated-platelets: An emerging component of the procoagulant response. J Thromb Haemost 2005; 3: 2185-92.
2. Prodan CI, Ross ED, Vincent AS, Dale GL. Coated-platelets are higher in amnestic versus non-amnestic patients with mild cognitive impairment. Alzheimer Dis Assoc Disord 2007; in press
3. Cheng A., Braunstein JB, Dennison C, Nass C, Blumenthal RS. Reducing global risk for cardiovascular disease: Using lifestyle changes and pharmacotherapy. Clin Cardiol 2002; 25: 205-12.
4. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. Am Coll Cardiol 2004; 43: 1731-7.
5. Pozner RG, Negrotto S, D'Atri LP, Kotler ML, Lazzari MA, Gomez RM, Schattner M. Prostacyclin prevents nitric oxide-induced megakaryocyte apoptosis. Br J Pharmacol 2005; 145: 283-92.
6. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91: 119-28.
7. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: Are we missing something? Am J Med 2006; 119: 113-6.
8. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894-8.
9. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents? Circulation 2004; 109: II18-26.
10. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 2000; 160: 825-31.
11. Zivin JA. Clinical trials of neuroprotective therapies. Stroke 2007; 38: 791-3.
12. Fonarow GC. In-hospital initiation of statin therapy in acute coronary syndromes: Maximizing the early and long-term benefits. Chest 2005; 128: 3641-51.
13. Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: A systematic review. Ethn Dis 2007; 17: 143-52.